This is why sending my DNA off to one of these companies to satisfy a curiosity always seemed risky to me. What is this company’s #1 asset? The DNA it has collected from millions of people. While 23andMe may be an ethical company that protects your privacy, there is nothing preventing it from selling that asset to a predatory firm or a hostile foreign actor.
Embattled genetic testing company 23andMe said on Tuesday that it’s started exploring strategic alternatives for a second time, which could include a sale of the company or its assets, a restructuring or a business combination.
The stock, which lost 82% of its value last year, fell 10% in extended trading and was briefly halted.
The announcement coincided with the release of 23andMe’s third-quarter results. Revenue in the company’s consumer services business dropped 8% to $39.6 million from $42.9 million in the same period last year.
The company said it will “need additional liquidity” to fund its operations, and it is looking to raise capital.
0 Comments